RU2020140694A - Способ лечения гипергликемии - Google Patents
Способ лечения гипергликемии Download PDFInfo
- Publication number
- RU2020140694A RU2020140694A RU2020140694A RU2020140694A RU2020140694A RU 2020140694 A RU2020140694 A RU 2020140694A RU 2020140694 A RU2020140694 A RU 2020140694A RU 2020140694 A RU2020140694 A RU 2020140694A RU 2020140694 A RU2020140694 A RU 2020140694A
- Authority
- RU
- Russia
- Prior art keywords
- blood glucose
- insulin
- verapamil
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (6)
1. Применение композиции, содержащей (R)-(+)-верапамил или его фармацевтически приемлемую соль и вещество для снижения уровня глюкозы в крови, для получения лекарственного средства для лечения сахарного диабета, где вещество для снижения уровня глюкозы в крови представляет собой инсулин или аналог инсулина.
2. Применение по п.1, где аналог инсулина представляет собой гларгин, деглудек или детемир.
3. Способ лечения сахарного диабета у субъекта, включающий введение субъекту эффективного количества (R)-(+)-верапамила или его фармацевтически приемлемой соли и вещества для снижения уровня глюкозы в крови, выбранного из группы, включающей инсулин и аналог инсулина.
4. Способ по п.3, где аналог инсулина представляет собой гларгин, деглудек или детемир.
5. Способ по п.3, где (R)-(+)-верапамил или его фармацевтически приемлемая соль и вещество для снижения уровня глюкозы в крови вводятся одновременно как одно лекарственное средство.
6. Способ по п.3, где (R)-(+)-верапамил или его фармацевтически приемлемая соль и вещество для снижения уровня глюкозы в крови вводятся независимо друг от друга как два лекарственных средства.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339131P | 2016-05-20 | 2016-05-20 | |
| US62/339,131 | 2016-05-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139578A Division RU2739255C2 (ru) | 2016-05-20 | 2017-05-17 | Способ лечения гипергликемии |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020140694A true RU2020140694A (ru) | 2021-01-25 |
| RU2020140694A3 RU2020140694A3 (ru) | 2021-10-08 |
Family
ID=60326464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020140694A RU2020140694A (ru) | 2016-05-20 | 2017-05-17 | Способ лечения гипергликемии |
| RU2018139578A RU2739255C2 (ru) | 2016-05-20 | 2017-05-17 | Способ лечения гипергликемии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139578A RU2739255C2 (ru) | 2016-05-20 | 2017-05-17 | Способ лечения гипергликемии |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9980935B2 (ru) |
| EP (1) | EP3413886A4 (ru) |
| JP (3) | JP6692903B2 (ru) |
| KR (3) | KR102200664B1 (ru) |
| CN (2) | CN108430467B (ru) |
| AU (1) | AU2017267006B2 (ru) |
| BR (1) | BR112018073688A2 (ru) |
| CA (2) | CA3114057A1 (ru) |
| HK (1) | HK1254471A1 (ru) |
| IL (1) | IL262994B2 (ru) |
| MX (1) | MX2018013943A (ru) |
| RU (2) | RU2020140694A (ru) |
| SG (1) | SG11201809899RA (ru) |
| TW (1) | TWI659738B (ru) |
| WO (1) | WO2017198177A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102200664B1 (ko) * | 2016-05-20 | 2021-01-08 | 센터 래버러토리스 아이엔씨 | 고혈당증의 치료 방법 |
| US10639292B2 (en) | 2018-04-20 | 2020-05-05 | Center Laboratories, Inc. | Method of treating hyperglycemia |
| EP3981401A1 (en) * | 2020-10-06 | 2022-04-13 | InSphero AG | Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic |
| BR112023022114A2 (pt) * | 2021-04-29 | 2024-01-30 | Ildong Pharmaceutical Co Ltd | Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9616549D0 (en) * | 1996-08-06 | 1996-09-25 | Chiroscience Ltd | Therapeutic product and its use |
| US20030092765A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil |
| EP1894567B1 (en) * | 2005-06-03 | 2012-08-15 | Mitsubishi Tanabe Pharma Corporation | Concomitant pharmaceutical agents and use thereof |
| RU2338521C1 (ru) * | 2007-02-28 | 2008-11-20 | Илья Николаевич Медведев | Способ быстрого снижения активности тромбопластиногенерации у лиц с метаболическим синдромом |
| EP2762150A1 (en) * | 2009-03-12 | 2014-08-06 | Nordic Bioscience A/S | Treatment of Diabetes and Metabolic Syndrome |
| CN101869708A (zh) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | 含有钙通道阻滞剂和双胍类降糖药物的药物组合物及其用途 |
| US8685934B2 (en) * | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| TWI410630B (zh) * | 2009-11-10 | 2013-10-01 | Ct Lab Inc | 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物 |
| EP2498757A1 (en) * | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
| EP2573088A1 (en) * | 2011-09-26 | 2013-03-27 | Prous Institute for Biomedical Research, S.A. | Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof |
| WO2015142865A2 (en) * | 2014-03-17 | 2015-09-24 | Massachusetts Institute Of Technology | Metakaryocidal treatments |
| AU2015341341A1 (en) | 2014-10-29 | 2017-04-27 | Center Laboratories, Inc. | Crystal forms of verapamil hydrochloride |
| KR102200664B1 (ko) * | 2016-05-20 | 2021-01-08 | 센터 래버러토리스 아이엔씨 | 고혈당증의 치료 방법 |
-
2017
- 2017-05-17 KR KR1020187012063A patent/KR102200664B1/ko active IP Right Grant
- 2017-05-17 CA CA3114057A patent/CA3114057A1/en not_active Abandoned
- 2017-05-17 MX MX2018013943A patent/MX2018013943A/es unknown
- 2017-05-17 BR BR112018073688-0A patent/BR112018073688A2/pt active Search and Examination
- 2017-05-17 SG SG11201809899RA patent/SG11201809899RA/en unknown
- 2017-05-17 RU RU2020140694A patent/RU2020140694A/ru not_active Application Discontinuation
- 2017-05-17 CN CN201780003723.9A patent/CN108430467B/zh active Active
- 2017-05-17 RU RU2018139578A patent/RU2739255C2/ru active
- 2017-05-17 CA CA3003319A patent/CA3003319C/en active Active
- 2017-05-17 KR KR1020217031124A patent/KR102423967B1/ko active IP Right Grant
- 2017-05-17 US US15/597,200 patent/US9980935B2/en active Active
- 2017-05-17 AU AU2017267006A patent/AU2017267006B2/en active Active
- 2017-05-17 TW TW106116239A patent/TWI659738B/zh active
- 2017-05-17 JP JP2018521403A patent/JP6692903B2/ja active Active
- 2017-05-17 EP EP17798740.1A patent/EP3413886A4/en not_active Withdrawn
- 2017-05-17 CN CN202110545191.XA patent/CN113384571A/zh active Pending
- 2017-05-17 WO PCT/CN2017/084746 patent/WO2017198177A1/en active Application Filing
- 2017-05-17 KR KR1020207037511A patent/KR20210000757A/ko not_active Application Discontinuation
-
2018
- 2018-04-20 US US15/957,956 patent/US10278943B2/en active Active
- 2018-10-23 HK HK18113557.8A patent/HK1254471A1/zh unknown
- 2018-11-13 IL IL262994A patent/IL262994B2/en unknown
-
2020
- 2020-02-27 JP JP2020032083A patent/JP2020100651A/ja active Pending
-
2022
- 2022-01-11 JP JP2022002081A patent/JP7266327B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6329487B2 (ja) | ２型糖尿病の治療プロトコル | |
| RU2020140694A (ru) | Способ лечения гипергликемии | |
| ES2398012T5 (es) | Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2 | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| JP2011241213A5 (ru) | ||
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| RU2016132342A (ru) | Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных | |
| JP2019517542A5 (ru) | ||
| RU2007127499A (ru) | Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| RU2013114376A (ru) | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа | |
| MX2013011174A (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| RU2016101064A (ru) | Состав с постоянным соотношением инсулина гларгина/ликсизенатида | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2016539921A5 (ru) | ||
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| JP2018509419A5 (ru) | ||
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| CN103933031B (zh) | 一种含有dpp‑4抑制剂和盐酸二甲双胍的复方制剂及其制备方法 | |
| JP2014504601A5 (ru) | ||
| Provilus et al. | Weight gain associated with antidiabetic medications | |
| ES2957268T3 (es) | Una combinación de sustancias para su uso en la terapia regenerativa en pacientes con diabetes mellitus tipo 1 | |
| De Galan et al. | Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus | |
| JP2008505087A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220201 |